Keyword: Monsanto

Bayer turns science into a verb with its new corporate campaign, “Why We Science"—the largest image push in the company's history.

In terms of share value loss, Bayer's Monsanto deal stands among the worst corporate deals in modern history.

Bayer's revamp just took another big step forward. After selling off Coppertone, the company agreed to hive off Dr. Scholl’s for $585 million.

Bayer hired a new external lawyer and set up a special committee to advise on the Roundup litigation, triggering talks of a potential settlement.

With angry investors and thousands of lawsuits bearing down, Bayer is scrambling to keep its head above water. Looks like relief isn’t coming soon.

More than half of Bayer shareholders gave a thumbs down to executives and their actions in 2018, the lowest approval rating for a German company since World War II.

China sales and older meds helped boost Bayer's pharma results, but those numbers couldn't eclipse concerns about mushrooming Monsanto litigation.

Bayer Chairman Werner Baumann could face a vote a no confidence from its top investor, BlackRock, Reuters reported.

The Monsanto acquisition "was and is a good idea," says Bayer chief executive, even as the company lost phase 1 of the first bellwether Roundup trial.

Bayer's sale of its animal health unit is attracting interest from a wide variety of players, including private equity firms and even rivals, a new report reveals.